(Reuters) – Organovo Holdings said on Monday its experimental drug to treat a type of fatty liver disease met the main goal in a mid-stage study, sending its shares up nearly 27% in premarket trade.
The non-steroidal drug, FXR314, helped significantly reduce liver fat in patients with metabolic function-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis.
FXR314 was also found to be safe and well-tolerated, Organovo said.
The company expects to present detailed findings of the study at an upcoming conference.
(Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
Comments